Let’s be honest — the word “biosimilar” still makes some people’s eyes glaze over. But if you work anywhere near pharmaceutical development, market access, or clinical research in Asia, biosimilars are not a background topic anymore. They are the conversation. And the numbers behind that conversation are genuinely remarkable.
Asia is rapidly becoming the most important battleground in global biosimilar development — and the stakes, both commercially and for patient access, could not be higher.
🌏 The Scale of What Is Actually Happening
The Asia-Pacific biosimilars market was valued at approximately $8.2 billion in 2024. By 2031, it is projected to reach $24.6 billion, growing at a compound annual growth rate of 17.1% — making it the fastest-growing biosimilars market on the planet by a considerable margin.
To put that in context: the global biosimilars market as a whole is growing at roughly 12.8% CAGR over the same period. Asia is not just participating in the biosimilars revolution. It is leading it.
Several structural forces are driving this:
- Patent expiry acceleration: More than $120 billion worth of originator biologic products face patent expiry globally between 2024 and 2030, with a significant proportion of those molecules having substantial Asian patient populations
- Healthcare cost pressure: Asian governments are under intense fiscal pressure to expand access to biologic therapies — particularly in oncology, autoimmune disease, and diabetes — without proportionally expanding healthcare budgets
- Manufacturing maturity: South Korea, China, India, and Japan have developed world-class biopharmaceutical manufacturing infrastructure capable of producing biosimilars to international quality standards
- Regulatory evolution: Regulatory frameworks across Asia have matured significantly, with dedicated biosimilar approval pathways now established in China, Japan, South Korea, India, and across ASEAN markets
💊 Where the Opportunities Are Genuinely Exciting
Oncology Biosimilars — The Largest Single Opportunity
Oncology represents the single largest opportunity within the rise of biosimilars in Asia. Biosimilar versions of trastuzumab, bevacizumab, and rituximab — three of the most widely used oncologic biologics globally — are now approved and commercially available across multiple Asian markets.
The access implications are profound. In markets where originator trastuzumab carried a treatment cost of $30,000–$70,000 per patient annually, approved biosimilar versions have entered at price points 40–70% lower — dramatically expanding the population of patients for whom HER2-positive breast cancer treatment is financially accessible.
A 2025 analysis of biosimilar trastuzumab uptake across five Asian markets found that biosimilar market penetration correlated directly with a 23–38% increase in treatment-eligible patient volumes — not because the patient population grew, but because cost barriers that previously excluded patients from treatment were removed.
South Korea — The Biosimilar Export Powerhouse
South Korea deserves particular attention in any serious discussion of the rise of biosimilars in Asia. Korean biopharmaceutical manufacturers — led by companies such as Celltrion and Samsung Bioepis — have established themselves as globally significant biosimilar developers, with products approved not just across Asia but in the European Union and other major regulated markets.
South Korea’s biosimilar exports reached approximately $2.1 billion in 2024, representing a 34% year-on-year increase. The country’s investment in biopharmaceutical manufacturing capacity — supported by deliberate government industrial policy — has created a competitive advantage that is structural rather than temporary.
China — Volume, Scale, and Domestic Competition
China’s biosimilar market operates at a scale that is genuinely difficult to comprehend from the outside. With a patient population of 1.4 billion, healthcare system reform driving aggressive cost containment, and a domestic biopharmaceutical industry that has invested heavily in biosimilar development capability, China represents both the largest single-country opportunity and the most intensely competitive biosimilar environment in the world.
China’s National Healthcare Security Administration (NHSA) volume-based procurement programme — which uses competitive tendering to drive biosimilar adoption across the public hospital system — has been transformative. In therapeutic categories where volume-based procurement has been applied to biosimilars, originator biologic market share has declined by 50–75% within 12–18 months of procurement implementation.
For international biosimilar developers, China’s market offers extraordinary volume potential. It also demands a clear-eyed assessment of the pricing dynamics that volume-based procurement creates.
⚠️ The Challenges That Do Not Get Enough Attention
Regulatory Fragmentation Across Asian Markets
Despite significant progress, the regulatory landscape for biosimilar approval across Asia remains fragmented in ways that create real operational complexity for developers pursuing multi-market strategies.
The core challenge is that there is no single Asian regulatory framework for biosimilars. Each major market operates its own approval pathway:
| Market | Regulatory Body | Biosimilar Pathway | Key Characteristic |
|---|---|---|---|
| China | NMPA | Dedicated biosimilar guidelines (2015, updated 2022) | Comparability exercise with reference product approved in China |
| Japan | PMDA | Biosimilar guidelines aligned with ICH Q5E | Strong emphasis on analytical comparability data |
| South Korea | MFDS | Biosimilar approval pathway since 2009 | One of Asia’s most mature and internationally recognised frameworks |
| India | CDSCO | Similar Biologics guidelines | Abbreviated clinical data requirements in some categories |
| ASEAN | Market-specific | Varies significantly by member state | Limited harmonisation; mutual recognition frameworks developing |
This fragmentation means that a biosimilar developer pursuing approval across China, Japan, South Korea, and three ASEAN markets is effectively managing five or more parallel regulatory submissions, each with distinct data requirements, reference product specifications, and review timelines. The regulatory investment required to execute that strategy is substantial — and it disproportionately favours larger, well-capitalised developers over smaller innovators.
Physician and Patient Confidence — The Adoption Gap
Regulatory approval and commercial adoption are not the same thing. Across multiple Asian markets, approved biosimilars face a persistent adoption gap driven by physician uncertainty about interchangeability, patient concerns about switching from originator products, and — in some markets — commercial incentives within the prescribing system that favour higher-priced originators.
A 2025 survey of oncologists across six Asian markets found that 41% expressed reservations about switching stable patients from originator biologics to biosimilars, despite acknowledging that the regulatory evidence base supported biosimilarity. The most commonly cited concern was not clinical efficacy — it was the absence of long-term real-world safety data specific to the Asian patient population.
Addressing this confidence gap requires investment in post-marketing surveillance programmes, real-world evidence generation, and physician education initiatives that go well beyond the regulatory approval process itself.
Pharmacovigilance Infrastructure Gaps
Biosimilars require robust pharmacovigilance systems capable of distinguishing adverse events attributable to the biosimilar from those associated with the reference biologic — and of tracking immunogenicity signals across large patient populations over extended time periods.
Pharmacovigilance infrastructure across Asian markets varies considerably. Japan and South Korea have mature, internationally recognised pharmacovigilance systems. Several ASEAN markets are still developing the infrastructure required to support the post-marketing surveillance commitments that biosimilar approvals increasingly require.
For developers, this creates a practical challenge: the post-marketing commitments attached to biosimilar approvals in markets with developing pharmacovigilance infrastructure can be more demanding — and more expensive to fulfil — than in markets with established systems.
💡 The Bigger Picture
The rise of biosimilars in Asia is not simply a pharmaceutical market story. It is a healthcare access story. Across the region, biologic therapies that were previously accessible only to patients in high-income urban centres — or not accessible at all — are becoming financially viable for a dramatically broader patient population.
That is genuinely significant. And it is happening because of the convergence of manufacturing investment, regulatory maturation, government procurement policy, and commercial competition that the biosimilar market in Asia now represents.
The challenges are real — regulatory fragmentation, adoption gaps, and pharmacovigilance infrastructure will not resolve themselves overnight. But the trajectory is clear. Asia’s biosimilar market is not approaching a tipping point. It has already passed one.
The developers, manufacturers, and market access teams that understand both the opportunity and the complexity of this landscape — in equal measure — are the ones who will define the next decade of biologic medicine access across the region.
